Silo Pharma terminates UMB license, enters evaluation license and option for CNS-homing peptides

Silo Pharma, Inc.

Terminates 2021 Master License Agreement with University of Maryland, Baltimore effective June 30, 2025.
Gains exclusive evaluation license for CNS-homing peptides for non-clinical research through March 31, 2026.
Holds option to negotiate a commercial license for neuroinflammatory disease; exercise requires $1,000 fee and plan.
Derived IP created during evaluation automatically assigned to UMB; if option exercised, it enters new license.
U.S. Government retains rights under Federal IP Policy; agreement subject to existing third-party commitments.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.